Phytosterols, Ezetimibe, and Cholesterol Metabolism
Information source: Washington University School of Medicine
Information obtained from ClinicalTrials.gov on October 19, 2009 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypercholesterolemia; Coronary Heart Disease
Intervention: Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Washington University School of Medicine Official(s) and/or principal investigator(s): Richard Ostlund, M.D., Principal Investigator, Affiliation: Washington University School of Medicine
Overall contact: Richard Ostlund, M.D., Phone: 314-362-7617, Email: rostlund@dom.wustl.edu
Summary
Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but
appear to have different mechanisms of action. The investigators hypothesis is that
phytosterols and ezetimibe given together will block cholesterol absorption nearly
completely. The investigators will perform a randomized, placebo-controlled crossover
feeding study in 25 subjects with greater than ideal levels of LDL cholesterol who do not
require anti-cholesterol drug treatment. Subjects will consume a baseline diet provided by
a feeding center that is deficient in phytosterols for three periods of 21 days in random
order. During period I placebo phytosterols and placebo ezetimibe will be given; during
period II placebo phytosterols and active ezetimibe will be given; during period III active
phytosterols and active ezetimibe will be given. Study endpoints are fecal cholesterol
excretion and percent cholesterol absorption determined by gas chromatography/mass
spectrometry, circulating phytosterol levels and circulating LDL cholesterol levels.
Clinical Details
Official title: Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3)
Study design: Basic Science, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Efficacy Study
Primary outcome: Cholesterol Absorption and Excretion
Secondary outcome: LDL cholesterol
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male or female of any race or ethnicity between 18 to 80 years of age;
- Body mass index between 20 - 35 kg/m2;
- LDL-cholesterol between 130 - 189 mg/dL based on the average of duplicate screening
measures. If the two LDL-C levels differ by more than 30 mg/dL, a third test will be
scheduled with all three results averaged;
- Free of chronic disease;
- Willing to eat only the foods that are provided by the Center during the diet
periods;
- Willing to abstain from the consumption of alcohol for 48-hours prior to blood draw
days;
- Willing to drink no more than 5 cups of caffeine-containing beverages a day.
Exclusion Criteria:
- Age < 18 or > 80 years;
- Based on duplicate screening laboratory values: 1)LDL-C >=190 mg/dL; 2)TG >=250
mg/dL;3)blood pressure >= 160 mm Hg systolic or 95 mm Hg diastolic;
- Documented presence of atherosclerotic disease;
- Diabetes mellitus;
- Renal, hepatic, endocrine, gastrointestinal, hematological or other systemic disease;
- Body mass index > 35;
- For women, pregnancy, breast feeding or postpartum < 6 months;
- For women, peri-menopausal;
- For women, sexually active but not practicing effective birth control methods;
- History of drug or alcohol abuse;
- History of depression or mental illness requiring treatment or medication within the
last 6 months;
- multiple food allergies or significant food preferences or restrictions that would
interfere with diet adherence;
- Chronic use of over-the-counter medication which would interfere with study endpoints
including laxatives and antacids;
- Lifestyle or schedule incompatible with the study protocol;
- Planned continued use of dietary supplements through the study trial;
- Taking any lipid-lowering, or other medications known to affect blood cholesterol.
Locations and Contacts
Richard Ostlund, M.D., Phone: 314-362-7617, Email: rostlund@dom.wustl.edu
Center for Advance Nutrition at Utah State University, Logan, Utah 84322-4715, United States
Additional Information
Starting date: April 2009
Last updated: March 16, 2009
|